Nivolumab: Does the Extended CheckMate-274 Results Prove It’s the Ultimate for MIBC? ASCO GU 2025
The Nivolumab CheckMate-274 trial reveals promising data on overall survival in muscle-invasive bladder cancer.
Related Articles
FDA Approves Opdivo / Nivolumab Plus Yervoy / Ipilimumab for MSI-H/dMMR Colorectal Cancer: A Precision Oncology Milestone
Get informed about Nivolumab MSI-H Colorectal and its FDA approval. Detailed insights from the CHECKMATE-8HW trial await.
Oncology Conferences 2025-2027: Full List & Details
Prepare for Oncology Conferences 2025 to 2027. Join leading meetings such as ASCO and SABCS for the latest in cancer research.
[2025] Lung & Genitourinary Cancer Updates – Medical Oncology Association of Southern California
Empowering Oncology Professionals with Knowledge, Insights, and Innovation. Medicus Networks, Inc. 45121 Morgan Heights Rd, Temecula, CA 92592 All Rights
Potential targeted therapy for pediatric brain cancer identified by Dana-Farber/Boston Children’s team | Dana-Farber Cancer Institute
An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in…
Suicidal ideation significantly higher among childhood cancer survivors
Childhood cancer survivors in Europe exhibited higher risk for suicidal ideation than the general population, according to results of a systematic review and meta-analysis.This finding…
Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction…
Peritumoral edema resolves infrequently in surgically treated patients with intracranial meningioma– a retrospective study of 279 meningioma patients
Journal of Neuro-Oncology – The resolution of peritumoral brain edema (PTBE) following surgery for intracranial meningioma (IM) is poorly understood. We hypothesized that PTBE represents…
ASTROgram for week of March 17- American Society for Radiation Oncology (ASTRO)
ASTRO’s weekly member newsletter for the week of March 17: ROCR Act reintroduced, Don’t miss 2025 Refresher, Leadership Pathway Program Awardees
Genomic Summary Results | EGRP/DCCPS/NCI/NIH
Resources for investigators to find and make publicly available genomic summary results (GSR) data from cancer research studies.
Artificial Intelligence (AI) Model, “HistoTME,” Aids in Predicting Response to Immunotherapy | CBIIT
NCI researchers debuted a new deep learning model that could help you decipher the cancer tumor’s microenvironment. The model holds a lot of promise for…